Added to YB: 2026-07-14
Pitch date: 2026-07-10
SDZNY [bullish]
Sandoz Group AG
-1.24%
current return
Author Info
No bio for this author
Company Info
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology.
Market Cap
CHF 36.4B
Pitch Price
CHF 67.50
Price Target
N/A
Dividend
1.18%
EV/EBITDA
20.47
P/E
40.20
EV/Sales
3.61
Sector
Pharmaceuticals
Category
growth
Sandoz: The Golden Decade of Biosimilars
SDZNY: Novartis spin-off, global leader in generics (70% sales) & biosimilars (30%). $11.1B 2025 net sales. Biosimilars +18% Q1'26, market to grow 19% CAGR to $122B by 2032 amid $200B+ patent cliff. 32 biosimilars in pipeline (incl Keytruda). Margins guided 21.7%→24-26% by 2028. 22x fwd P/E (vs 14 median) but FCF yield rose to 2.8%; growing into valuation. Textbook Weinstein breakout above CHF67. Risks: price erosion, Pfizer/Amgen competition, litigation.
Read full article (7 min)